Moderna’s First mRNA Manufacturing Facility in Australia

We are proud to celebrate the opening of Australia’s first large-scale mRNA manufacturing facility, the Moderna Technology Centre – Melbourne (MTC-M), at Monash University’s Technology Precinct in Clayton, Victoria. The 10,000-square-meter facility is the first of its kind in the Southern Hemisphere and has the capacity to produce up to 100 million doses annually, supplying essential vaccines for seasonal and non-seasonal disease. MTC-M positions Australia as one of the only countries globally with end-to-end mRNA vaccine capabilities and represents a critical step in strengthening the nation’s health resilience and ensuring rapid response capabilities.

Local Production for Greater Health Independence

Located within a world-leading biomedical and technology precinct in Melbourne, the facility will provide Australia with a robust domestic mRNA production capacity, subject to regulatory approval. This local manufacturing capability will enable faster access to essential vaccines, allowing Australia to respond efficiently to future pandemics and public health challenges. By producing doses directly in Melbourne, Moderna is supporting a resilient, self-sufficient health infrastructure for the country and the region, including job creation, and fostering the growth of a vibrant mRNA and biotech ecosystem.

Supporting a Thriving R&D mRNA Ecosystem

A vibrant ecosystem is a complex one — it requires manufacturing capabilities, expertise in clinical trials, robust research and product development and a supportive regulatory framework that fosters progress and productivity. In just a few years, Moderna has invested in a number of R&D initiatives and has brought 14 clinical trials to Australia to investigate new therapies and vaccines including for melanoma, cancer, flu and COVID-19 combination vaccine and a cytomegalovirus (CMV) vaccine. mRNA technology holds immense potential for addressing critical health issues and this investment is a forward-looking strategy to enhance Australia's healthcare capabilities for generations to come.

Part of Moderna’s Global Resilience Network

MTC-M is part of Moderna’s global expansion effort that includes strategic manufacturing investments in Australia, Canada, and the United Kingdom. These sites bring essential production capabilities closer to regional populations, strengthening health security. Through this investment in Australia, Moderna is helping to build a future where critical vaccines are readily available when and where they’re needed most.